Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.
Last updated:
March 30, 2026
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant.
Last updated:
March 30, 2026
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Venclexta, in combination with ibrutinib, for the treatment of adult patients with relapsed or
Last updated:
March 29, 2026
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Calquence, in combination with venetoclex, for the treatment of patients with previously
Last updated:
March 29, 2026
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
In combination with ibrutinib, is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Last updated:
March 29, 2026
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Growth hormone deficiency
Last updated:
March 27, 2026
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.
Last updated:
March 25, 2026
Status:
Active negotiation
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Last updated:
March 20, 2026
Status:
Active negotiation
Manufacturer:
Biogen Canada Inc.
Indication:
Amyotrophic Lateral Sclerosis (ALS)
Last updated:
March 18, 2026
Status:
Active negotiation
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic hepatitis delta virus (HDV) infection
Last updated:
March 16, 2026